First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Mirati Therapeutics Inc.
Pheon Therapeutics
Novartis
Eli Lilly and Company
Mirati Therapeutics Inc.
University of Iowa
Mirati Therapeutics Inc.
ADC Therapeutics S.A.
HiberCell, Inc.
Stanford University
Northwell Health
MacroGenics
Fox Chase Cancer Center
Gilead Sciences
Takeda
Duke University
West Virginia University
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Prism Pharma Co., Ltd.
GI View Ltd.
National Cancer Institute (NCI)
Tufts Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Calando Pharmaceuticals
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Cancer Research UK
Case Comprehensive Cancer Center
St. Luke's-Roosevelt Hospital Center
Millennium Pharmaceuticals, Inc.